A Systematic Overview of Chemotherapy Effects in Indolent Non-Hodgkin's Lymphoma

References

• Lennert K, Feller AC. Histopathology of non-Hodgkin's lymphomas (Based on the updated Kiel classification). Springer-Verlag, 1990.
   Google Scholar
• Harris LH, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92.
   PubMed Web of Science ®Google Scholar
• Longo DL. What's the deal with follicular lymphomas? J Clin Oncol 1993; 11: 202-8. (L1)
   PubMedGoogle Scholar
• Gall EA, Mallory TB. Malignant lymphoma: A clinico-pathologic survey of 618 cases. Am J Pathol 1942; 18: 381-429. (01)
   PubMedGoogle Scholar
• Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470-80. (P1/148)
   Google Scholar
• Horning SJ. Low-grade lymphoma 1993: State of the art. Ann Oncol 1994; 5 (Suppl 2): 23–7. (L1)
   Google Scholar
• Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin's lymphomas - II. Prognostic factors: What do they mean? Eur J Cancer 1996; 32A: 480-90. (01)
   Google Scholar
• Foussard C, Desablens B, Sensebe L, et al. Is the interna-tional prognostic index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. Ann Oncol 1997; 8: 49-52. (02)
   Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, et al. Appli-cability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–8. (02)
   Google Scholar
• Hoppe RT. The role of radiation therapy in the management of the non-Hodgkin's lymphoma. Cancer 1985; 55: 2176-83. (L2)
   Google Scholar
• Longo DL, Mauch P, DeVita VT, et al. Lymphocytic lymphomas. In: DeVita VT, Hellman S, Rosenberg S A, eds. Cancer: Principles & Practice of oncology. Philadelphia: Lippincott, 1993: 1859–927. (L1)
   Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-90. (R1/177)
   Google Scholar
• Portlock CS. Management of the low-grade non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 51-9. (L1)
   Google Scholar
• Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin's lymphomas.-I. The possibility of cure. Eur J Cancer 1996; 32A: 470–9. (C1/398)
   Google Scholar
• Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and II indolent lymphomas at the Na-tional Cancer Institute. Int J Radiat Oncol Biol Phys 1988; 14: 417-24. (R3/38)
   Google Scholar
• Paryani SB, Hoppe RT, Cox RS, et al. Analysis of non-Hodgkin's lymphomas with nodular and favorable histolo-gies, stages I and II. Cancer 1983; 52: 2300-7. (R2/124).
   Google Scholar
• Carde P, Burgers JM, van Glabbeke M, et al. Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: The 1975–1980 EORTC controlled lymphoma trial. Radiother Oncol 1984: 301–12. (C2/124)
   Google Scholar
• Kelsey SM, Newland AC, Vaughan-Hudson G, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiother-apy alone in low grade, localised non-Hodgkin's lymphoma. Med Oncol 1994; 11: 19-25. (C1/148)
   Google Scholar
• Landberg TG, Halansson LG, Möller TR, et al. CVP-remis-sion-maintenance in stage I-II non-Hodgkin's lymphomas. Cancer 1979; 44: 831-8. (C3/55)
   Google Scholar
• Monfardini S, Banfi A, Bonadonna G, et al. Improved five-year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int .1- Radiat Oncol Biol Phys 1980; 6: 125–34. (C3/96)
   PubMed Web of Science ®Google Scholar
• Nissen NI, Ersboll J, Sand Hansen H, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983; 52: 1-7. (C3/73)
   Google Scholar
• Yahalom J, Varsos G, Fuks Z, et al. Adjuvant cyclophos-phamide, doxorubicine, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Cancer 1993; 71: 2342-50. (C3/44)
   Google Scholar
• Phillips DL. Radiotherapy in the treatment of localised non-Hodgkin's lymphoma (Report no 16). Clin Radiol 1981; 32: 543-6. (C2/230)
   Google Scholar
• Besa P C, McLaughlin P W, Cox J D, et al. Long-term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 1995; 75: 2361-7. (R2/144)
   Google Scholar
• McLaughlin P, Fuller L, Redman J, et al. Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 1991; 2 (Suppl 2): 137–40. (P2/44)
   Google Scholar
• Seymour JF, McLaughlin P, Fuller LM, et al. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 1996; 7: 157-63. (P2/91)
   Google Scholar
• Jelic S, Frim O, Jovanovic V, et al. Watch and wait policy for patients with non Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery. Ann Oncol 1996; 7 (Suppl 3): 55 Abstr. (P3/50)
   Google Scholar
• Soubeyran P, Eghbali H, Trojani M. Wait and see policy in stage I follicular lymphoma. Ann Oncol 1996; 7 (Suppl 3): 144 Abstr. (P3/26)
   Google Scholar
• Portlock CS, Rosenberg SA. No initial therapy for stage III and IV lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 10-3. (R2/156)
   Google Scholar
• Brice R, Bastion Y, Lepage E, et al. Comparison in low-tu-mor-burden follicular lymphomas between an initial no-treat-ment policy, prednimustine, or interferon alpha: A randomized study from the Groupe D'Etudes des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 1110-7. (C1/193)
   Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471-5. (R2/83)
   Google Scholar
• Martinsson U, Glimelius B, Hagberg H, et al. Primarily asymptomatic low-grade non-Hodgkin lymphomas: Predic-tion of symptom-free survival and total survival. Eur J Haematol 1989; 43: 332-8. (R2/64)
   Google Scholar
• Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment. Semin Hematol 1988; 25: 11-6. (C3/89)
   Google Scholar
• Cavallin-Stal E, Moller TR. Prednimustine v cyclophos-phamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: Results of a National Cancer Care Program in Sweden. Semin Oncol 1986; 1 (Suppl 1): 19–22. (C1/217)
   Google Scholar
• Hoppe RT, Kushlan P, Kaplan HS, et al. The treatment of advanced stage favorable histology non-Hodgkin's lymphomas: A preliminary report of a randomized trial comparing single-agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592-8. (C3/51)
   Google Scholar
• Jones SE, Rosenberg SA, Kaplan HS, et al. Non-Hodgkin's lymphomas. II Single agent chemotherapy. Cancer 1972; 30: 31-8. (R2/110)
   Google Scholar
• Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histologic type. Br Med J 1978; 1: 533-7. (C2/66)
   Google Scholar
• Israels LG, Galton DA, Till M, et al. Clinical evaluation of CB 1348 in malignant lymphoma and related diseases. Ann New York Acad Sciences 1958; 68: 915-25. (P2/109)
   Google Scholar
• Kennedy BJ, Bloomfield C, Kiang DT, et al. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 1978; 41: 23-8. (C3/29)
   Google Scholar
• Aviles A, Duque G, Talavera A, et al. Interferon Alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996; 20: 495-9. (C2/98)
   Google Scholar
• Bonadonna G, Monfardini S. Chemotherapy of non-Hodgkin's lymphomas. Cancer Treat Rev 1974; 1: 167-81. (L1)
   PubMedGoogle Scholar
• Pott-Hoeck C, Hiddemann W. Purine analogs in the treat-ment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6: 421–33. (L1)
   Google Scholar
• Saven A, Emanuele S, Kosty M, et al. 2-chlorodeoxya-denosine activity with untreated, indolent non-Hodgkin's malignant lymphoma. Blood 1995; 86: 1710-6. (P2/28)
   Google Scholar
• Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514–9. (P1/49)
   Google Scholar
• Tallman MS, Hakimian D. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74. (L1)
   PubMedGoogle Scholar
• Velasques W, Lew D, Miller T, et al. SWOG 95–01: A phase II trial of a combination of fludarabine and mitoxantrone in untreated advanced low-grade lymphoma: An effective well-tolerated therapy. Proc Am Soc Clin Oncol 1998; 18: 27(Abstr). (P3/67)
   Google Scholar
• Marcus RE, Eghbali H, Monfardini S, et al. Preliminary results from a prospective randomised phase III trial of fludarabine vs CVP chemotherapy in newly diagnosed pa-tients with stage III & IV low grade NHL, VII Int Conf Malignant Lymphoma, Lugano 1999; 217 Abstr. (C3/381)
   Google Scholar
• Ezdinli EZ, Anderson JR, Melvin F, et al. Moderate vs aggressive chemotherapy of nodular lymphocytic poorly dif-ferentiated lymphoma. J Clin Oncol 1985; 3: 769-75. (C3/ 128)
   Google Scholar
• Glick JH, Barnes JM, Ezdinli EZ, et al. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920-5. (C3/52)
   Google Scholar
• Portlock CS, Rosenberg SA, Glatstein E, et al. Treatment of advanced non-Hodgkin's lymphomas with favorable histolo-gies: preliminary results of a prospective trial. Blood 1976; 47: 747-56. (C3/63)
   Google Scholar
• Anderson T, Bender RA, Fisher RI, et al. Combination chemotherapy in non-Hodgkin's lymphoma: Results of long-term follow-up. Cancer Treat Rep 1977; 61: 1057-66. (P2/ 31)
   Google Scholar
• Kimby E, Björkholm M, Gahrton G, et al. Chlorambucil/ prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5 (Suppl 2): 67–71. (C1/259)
   Google Scholar
• Lenhard RE, Prentice RL, Owens AH, et al. Combination chemotherapy of the malignant lymphomas. Cancer 1976; 38: 1052-9. (C3/13)
   Google Scholar
• Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy ("CHOP-Bleo") in advanced non-Hodgkin's malignant lymphoma. Blood 1977; 49: 325-33. (P3/8)
   Google Scholar
• Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy. J Clin Oncol 1993; 11: 644-51. (R1/415)
   Google Scholar
• Meerwaldt JH, Carde P, Burgers JM, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys 1991; 21: 1167-72. (C2/84)
   Google Scholar
• Unterhalt M, Herrmann R, Tiemann, et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia 1996; 10: 836–43. (Cl 442)
   PubMed Web of Science ®Google Scholar
• Al-Ismail S, Whittaker J, Gough J. Combination chemother-apy including epirubicin for the management of non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1987; 21: 1379–81. (C3/100)
   Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608–14. (C1/242)
   Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16: 2332–8. (C1/242)
   Google Scholar
• Anderson JW, Smalley RV. Interferon alpha plus chemotherapy for non-Hodgkin's lymphoma: five-year fol-low-up. N Engl J Med 1993; 329: 1821-2. (C1/249)
   Google Scholar
• Smalley R, Weller E, Hawkins M, et al. Interferon in non-Hodgkin's lymphoma an update of the ECOG I-COPA trial (E6484). Blood 1998; 92 (Suppl 1): 486 Abstr. (C3/291)
   Google Scholar
• Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon alpha-2b in the induction and maintenance treat-ment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16: 1538-46. (C1/155)
   Google Scholar
• Chisesi T, Congiu M, Contu A, et al. Randomized study of chlorambucil (CB) compared to interferon (alpha-2b) com-bined with CB in low-grade non-Hodgkin's lymphoma: an interim report of randomized study. Eur J Cancer 1991; 27 (Suppl 4): 31–3. (C3/63)
   Google Scholar
• Peterson BA, Petroni G, Oken MM, et al. Cyclophos-phamide versus cyclophosphamide plus interferon alpha-2b in follicular low-grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7489). Proc Am Soc Clin Oncol 1993; 12: 366(Abstr). (C3/581)
   Google Scholar
• Peterson BA, Petroni GR, Oken MM. Cyclophosphamide versus cyclophosphamide plus interferon alpha-2b in follicu-lar low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1997; 16: 48(Abstr). (C3/581)
   Google Scholar
• Price CG, Rohatiner AZ, Steward W, et al. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991; 2 (Suppl 2): 141–5. (C3/108)
   Google Scholar
• Rohatiner A, Crowther D, Radford J, et al. The role of interferon in follicular lymphoma. Proc Am Soc Clin Oncol 1996; 15: 1285(Abstr). (C3/204)
   Google Scholar
• Cole B, Solal-Céligny P, Gelber R, et al. Quality-of-life-ad-justed analysis of Interferon Alpha-2b treatment for ad-vanced follicular lymphoma: An aid to clinical decision making. J Clin Oncol 1998; 16: 2339-44. (C1/242)
   Google Scholar
• Hiddemann W, Griesinger F, Unterhalt M. Interferon alpha for the treatment of follicular lymphomas. Cancer J Sci Am 1998; 4: 13-8. (L1)
   Google Scholar
• Pigaditou A, Rohatiner AZ, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20: 24-7. (R2/ 88)
   Google Scholar
• Hiddemann W, Unterhalt M, Pott C, et al. Fludarabine single agent therapy for relapsed low-grade lymphomas: A phase 11 study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 1993; 20: 28-31. (P1/38)
   Google Scholar
• Hochster HS, Kim K, Green MD, et al. Activity of fludara-bine in previously treated non-Hodgkin's lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28-32. (P1/62)
   Google Scholar
• Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-4. (P2/67)
   Google Scholar
• Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 1991; 64: 120-3. (P1/50)
   Google Scholar
• Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine: An active agent in the treatment of previously-treated and un-treated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575-8. (P3/21)
   Google Scholar
• Hoffman M, Tallman MS, Hakimian D, et al. 2-chlorodeoxyadenosine is an active salvage therapy in ad-vanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 20: 24-7. (P2/21)
   Google Scholar
• Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxya-denosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371-7. (P1/40)
   Google Scholar
• Klasa R, Meyer R, Shustik C, et al. Phase III trial compar-ing fludarabine to CVP in patients with recurrent low grade non-Hodgkin's lymphomas (Ig-HL). VII Int Conf on Malign Lymph. Lugano 1999; 220 Abstr. (C3/91)
   Google Scholar
• McLaughlin P, Hagemeister FB, Romaguera JE, et al. Flu-darabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-8. (P2/51)
   Google Scholar
• Zinzani PL, Bendandi M, Magagnoli F, et al. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 379-83. (P1/48)
   Google Scholar
• Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148-52. (P2/24)
   Google Scholar
• Rohatiner AZ. Interferon alpha in lymphoma. Br J Haema-tol 1991; 79 (Suppl 1): 26–9. (L1)
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95. (P1/37)
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for re-lapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33. (P1/166)
   Google Scholar
• Piro LD, White CA, Grillo-López AJ, et al. Extended Ritux-imab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–61. (P1/37)
   Google Scholar
• Kaminski MS, Zazadny KR, Francis IR, et al. Radioim-munotherapy of B-cell lymphoma with [13II]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65. (P2/9)
   Google Scholar
• Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-an-tibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24. (P2/19)
   Google Scholar
• Czuzman M, Grillo-Lopez AJ, Saleh M, et al. IDEC-C2B8/ CHOP chemoimmunotherapy in patients with low-grade lymphoma: interim clinical and bc1-2 (PCR) results. Ann Oncol 1996; 7 (Suppl 1): 56 Abstr. (P3/27)
   Google Scholar
• Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of Rutimax in combination with CHOP chemotherapy in patients with previously un-treated intermediate- or high-grade NHL. Proc Am Soc Clin Oncol 1998; 17: 7 Abstr. (P3/31)
   Google Scholar
• Freedman AS, Takvorian T, Anderson KC, et al. Au-tologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-91. (R1/100)
   Google Scholar
• Bastion Y, Price P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 pa-tients with poor prognosis follicular lymphoma. Blood 1995; 86: 3257-62. (P1/60)
   Google Scholar
• Bierman P, Vose J, Anderson J, et al. High dose therapy with autologus hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-50. (R1/100)
   Google Scholar
• Colombat P, Donadio D, Fouillard L, et al. Value of autologous bone marrow transplantation in follicular lym-phoma: a France Autograffe retrospective study of 42 pa-tients. Bone Marrow Transplant 1994; 13: 157-62. (R2/42)
   Google Scholar
• Foran JM, Apostolidis J, Papamichael D. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre. Ann Oncol 1998; 9: 865–9. (P2/27)
   Google Scholar
• Freedman A, Gribben J, Neuberg D, et al. High-dose ther-apy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-6. (P1/83)
   Google Scholar
• Gorin NC, Lopez M, Laporte JP, et al. Preparation and successful engraftment of purified CD34bone marrowprogenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 1647-54. (P3/15)
   Google Scholar
• Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bc1-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57. (R2/134)
   Google Scholar
• Haas R, Moos M, Motile R. High-dose therapy with periph-eral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transpl 1996; 17: 149-55. (P1/48)
   Google Scholar
• Morel P, Laporte J, Lopez M, et al. Autologus bone marrow transplantation as consolidation therapy may prolong remis-sion in newly diagnosed high risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995; 9: 576-82. (R2/34)
   Google Scholar
• Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-84. (P1/64)
   Google Scholar
• Schouten H, Colombat P, Verdonck L. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. Ann Oncol 1994; 4 (Suppl 2): 147–9. (R1/92)
   Google Scholar
• Sharp J, Kessinger A, Mann S, et al. Outcome of high dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 124: 214-9. (P1/65)
   Google Scholar
• Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged periph-eral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transpl 1998; 21: 383-9. (P1/49)
   Google Scholar
• Williams C, Goldstone A, Pearce R, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Trans-plant lymphoma registry. J Clin Oncol 1996; 14: 2454-64. (R1/448)
   Google Scholar
• Schouten HC, Kvaloy S, Sydes M, et al. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodkgin's lymphoma (NHL). Ann Oncol 2000; 11 (Suppl 1): 91–4. (C3/140)
   Google Scholar
• van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 1995; 13: 1096-102. (P3/10)
   Google Scholar
• Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologus versus allogenic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-5. (P1/66)
   Google Scholar
• Verdonck LF, Dekker AW, Lokhorst HM, et al. Allogeneic versus autologous bone marrow transplantation for refrac-tory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-5. (R2/28)
   Google Scholar
• van Besien K, Sobocinski KA, Rowlings PA. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-6. (R1/113)
   Google Scholar